Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
26.04.08 - 18:17 ... source : Schering-Plough
... First Large Study Comparing Leading Hepatitis C Therapies Provides Important Insights to Help Guide Clinical PracticeMILAN, Italy, April 26, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Final results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C, were presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), providing important insights that may help guide clinical practice for physicians worldwide treating this serious and potentially life-threatening disease. The IDEAL study compared combination therapy with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP),(1) as well as a lower dose of PEGINTRON in an investigational combination with REBETOL ...» Next (HTML)
Similar news
100% | 14.03.08 - 19:16 ... source : Total
... chaired by Jean Privey, met on March 14, 2008 and approved the final accounts for the year ending December 31, 2007. Net income in 2007 increased 2.5% to $334.4 million, compared to $326.4 million in 2006. The oil production of ...
99% | 13.03.08 - 15:22 ... source : Benetton
... EBIT 243 million euro (+35%) Net income 145 million euro (+16%) Ordinary EBITDA up by over 27% Ponzano, 21 February 2008 - h. 2:20 p.m. CET. The Benetton Group Board meeting today viewed the preliminary results for the 2007 financial ...
99% | 06.03.08 - 09:10 ... source : Enel
... of the mandatory public tender offer (PTO) launched on the entire share capital of the Russian generation company OAO OGK-5 (OGK-5), Enel Investment Holding B.V. (EIH, a wholly-owned Dutch subsidiary of Enel S.p.A.) informs that it owns 59.80% of OGK-5's ...
96% | 17.04.08 - 15:48 ... source : Schering-Plough
... a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that final results of the IDEAL study as well as from several other clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) ...
94% | 01.04.08 - 20:07 ... source : Merck
... dose-ranging study of patients hospitalized with acute heart failure syndrome and renal impairment treatment with rolofylline, an investigational adenosine A1 receptor antagonist in development by Merck & Co., Inc., administered with intravenous (IV) loop diuretics was associated with improved dyspnea ...
